How to Get Insurance to Pay for Rehab: Authorizations, Denials, and the 2026 Appeal Rules

Almost nobody pays a rehab facility’s advertised price. What people actually pay is whatever survives a negotiation they did not know they were part of, conducted in a vocabulary they were never taught, on a clock that started running the moment someone said the word detox. Our wider independent research on what addiction treatment actually costs exists because that vacuum is where overpayment happens.

That is the honest framing of this subject. Getting insurance to pay for addiction treatment is not a purchase. It is an authorization process, and the people who do well at it are not the ones with the best plans. They are the ones who understood, before the first phone call, what their insurer is legally obligated to do, what it is permitted to refuse, and which deadline it is quietly hoping they will miss.

Why the Type of Health Plan You Have Decides Almost Everything About Getting Rehab Covered

Before any of the tactics matter, you need to know which regulatory universe your plan sits in, because that single fact controls who writes the rules, who enforces them, and where a refusal gets escalated. Two people with identical diagnoses and identical treatment plans can face completely different processes purely because one works for a large employer and the other buys coverage on an exchange.

The distinction that catches most families off guard is between fully insured and self-funded employer coverage. A self-funded plan means your employer pays the claims itself and hires an insurance company only to administer them. The card in your wallet says Aetna or Cigna, but the money is your employer’s, the plan is governed by federal law rather than your state’s insurance code, and your state insurance commissioner has no authority over it. Roughly two-thirds of covered workers in the United States are in this category and almost none of them know it.

There is one practical instruction that follows from this table. Ask your human resources department, in writing, whether your plan is self-funded or fully insured, and ask for the summary plan description. Do not ask the customer service line printed on your card. That line belongs to the administrator, and administrators answer questions about process, not about who holds the legal obligation.

If you are still at the stage of working out what any of this is likely to cost before insurance enters the picture, our research on what behavioral health rehab treatment costs in the United States sets out the underlying price structure that insurers negotiate against.

The Federal Laws That Give You Real Leverage When an Insurer Refuses to Cover Addiction Treatment

Two federal statutes do the heavy lifting, and understanding the difference between them is what separates an appeal that works from one that reads like a complaint.

The first is the Affordable Care Act, which made mental health and substance use disorder services one of the ten essential health benefits. In plain terms: most individual and small group plans cannot simply omit addiction treatment from the benefit package. Large employer plans are not bound by the essential health benefit list in the same way, which is a gap many people discover at the worst possible moment.

Large employer plans are not bound by the essential health benefit list in the same way, a gap we return to in our analysis of how insurance reshapes American treatment pricing.

The second is the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act, usually shortened to MHPAEA. Parity is widely misunderstood as a coverage mandate. It is not. MHPAEA does not require a plan to cover residential addiction treatment at all. What it requires is that where a plan does cover mental health and substance use benefits, it cannot apply harsher financial requirements or treatment limitations to those benefits than it applies to comparable medical and surgical care.

The 2026 Parity Enforcement Picture Is Genuinely Unsettled, and Honest Guides Should Say So

Here is where most competing articles are quietly out of date. In September 2024, the Departments of Labor, Health and Human Services, and Treasury issued a final rule that substantially tightened parity requirements, including a mandate that plans demonstrate meaningful benefits in every classification and collect outcomes data showing no material differences in access. Employer groups sued. In May 2025, the Departments announced they would not enforce the new portions of that rule while they reconsidered it, and on 30 March 2026 they told the court they would no longer defend the 2024 regulations at all, signalling significant revisions and adding new rulemaking to the spring 2026 regulatory agenda with a target of 31 December 2026. The court has asked for a status update by 30 September 2026.

This matters to you in a specific, non-abstract way. The statute itself has not changed. MHPAEA’s underlying obligations, including the requirement introduced by the Consolidated Appropriations Act of 2021 that plans prepare and produce a written comparative analysis of their nonquantitative treatment limitations on request, remain in force and remain enforceable. What is in limbo is the more prescriptive 2024 regulatory layer sitting on top of it.

The practical translation: keep asking for the comparative analysis, because you are still entitled to it. But do not build an appeal that depends on the 2024 rule’s newer requirements, because an insurer can accurately reply that those provisions are subject to a nonenforcement policy. Anchor the argument in the statute instead.

How Much Your Plan Can Legally Require You to Pay Out of Pocket in 2026 Before Coverage Absorbs the Rest

Every non-grandfathered plan has a ceiling on what you can be charged in deductibles, copays, and coinsurance for essential health benefits in a plan year. Once you cross it, the plan pays everything else for the remainder of the year. For residential addiction treatment, which is expensive and front-loaded, most people who use in-network care hit that ceiling inside the first month, which reframes the whole question. You are usually not asking what a thirty-day stay costs. You are asking whether you can reach your out-of-pocket maximum and whether the care you want counts toward it.

The 2026 limits jumped sharply. HHS originally published lower figures, then replaced them after finalizing a revised methodology for the premium adjustment percentage that now factors in individual market premium growth.

The self-only ACA ceiling rose roughly 15 percent between 2025 and 2026. Family coverage moved by the same proportion. Figures published by HHS; the 2026 numbers replace an earlier, lower set based on the previous methodology.

For readers weighing domestic prices against treatment abroad, the arithmetic changes considerably once an out-of-pocket ceiling is in play, and our comparisons of rehab costs across different countries and how addiction treatment pricing is structured internationally are worth reading beside this section rather than instead of it.

The Step-by-Step Sequence That Gets a Detox or Residential Admission Authorized Rather Than Refused

Authorization is a documentation contest, and it is usually lost before the clinical argument is ever made. The order below reflects how the process actually runs, not how it is described in brochures.

Step One: Get the Plan Documents Before You Get Anyone’s Opinion

Request the summary plan description if you have employer coverage, or the evidence of coverage if you buy your own. Then request the specific clinical criteria the plan uses for substance use disorder level-of-care decisions. Plans are generally required to provide these on request, and the request itself is useful because it puts a date on the record.

Step Two: Confirm the Benefit Category, Not Just Whether Rehab Is Covered

Ask about each level of care separately: medically managed withdrawal, residential treatment, partial hospitalization, intensive outpatient, standard outpatient, and medications for opioid use disorder. A plan can cover four of these generously and treat the fifth as a carve-out. Ask which network tier each falls into, and ask whether residential treatment is subject to a day limit or a per-episode limit. Our overview of the levels of care we cover across the treatment continuum is a useful reference for keeping the terminology straight while you are on the phone.

Step Three: Have the Clinical Assessment Documented Against the Criteria the Insurer Uses

This is the single highest-leverage step and the one most commonly skipped. An assessment that concludes residential care is appropriate, without documenting why less intensive care is insufficient, invites a denial. An assessment that walks through each dimension of the criteria the insurer applies is much harder to refuse. More on those criteria in the next section.

Step Four: Obtain Prior Authorization in Writing, With a Reference Number and an Approved Date Range

Verbal confirmation from an admissions department is not authorization. Facilities routinely tell families their insurance has been verified, which means only that the facility checked the policy is active and has behavioral health benefits. It is not a promise of payment, and it is not a promise about how many days will be covered.

Step Five: Track Concurrent Review Dates Yourself Rather Than Trusting the Facility To

Residential stays are almost never authorized in full at admission. Insurers approve a short initial block, then require clinical updates to extend. The most common cause of a mid-treatment coverage collapse is a missed concurrent review, and the person who pays for that administrative failure is the patient. Write the next review date on a calendar the day you are admitted, and ask the utilization review contact at the facility to confirm each extension in writing.

Step Six: Keep a Dated Log of Every Call, Name, and Reference Number

This sounds like bureaucratic overkill until an appeal turns on whether a plan representative told you something on a particular Tuesday. A log costs nothing and has resolved a great many disputes without anyone reaching an independent reviewer.

Why the ASAM Criteria Are the Language Your Insurer Actually Speaks About Level of Care

When an insurer says residential treatment is not medically necessary, it is almost never making that judgment freehand. It is applying a published standard, and for substance use disorders that standard is overwhelmingly the ASAM Criteria, produced by the American Society of Addiction Medicine. More than thirty states require licensed substance use providers to use them, and every major commercial payer uses them as the basis for prior authorization and concurrent review.

The criteria assess a person across multiple dimensions rather than by substance or by diagnosis alone: withdrawal risk, other medical conditions, psychiatric and cognitive status, readiness to change, relapse and continued use risk, and the recovery environment. A level of care is recommended by the combined dimensional profile. This is why two people using the same substance at the same frequency can legitimately be placed at different levels, and why the ladder of clinical intensity across levels of care matters more to your final bill than the name of the facility.

The fourth edition, published in October 2023, restructured the framework substantially, adding a dimension, removing a level from the specialty continuum, and shifting from an episodic model toward chronic care. Adoption is staggered and messy, which creates a live risk of documenting to the wrong edition:

The practical instruction is short. Ask the insurer, in writing, which edition and which criteria set it is applying to this decision, and ask the assessing clinician to document to that edition. A denial issued against the wrong standard is a denial with a defect in it.

What Insurers Actually Deny, How Often They Deny It, and What the Federal Data Reveals About Appeals

Because the Affordable Care Act requires marketplace insurers to report claims and appeals data, there is one segment of the market where this is measurable rather than anecdotal. KFF’s analysis of the 2024 federal data is the most recent available and it is unusually instructive.

Across HealthCare.gov plans, roughly 85 million in-network claims were denied in 2024. In-network denial rates ranged from 3 percent to 36 percent depending on insurer and state. Consumers appealed fewer than 1 percent of those denials, filing at least 262,982 internal appeals. Insurers upheld 165,863 of them, about 66 percent. Only 5,881 external appeals were filed, roughly 4 percent of the internal appeals that had been upheld.

Read those numbers in the other direction and the picture changes. Roughly a third of the denials that were appealed did not survive the appeal. And the reported reasons for in-network denials do not look like clinical disagreement at all:

Two conclusions follow, and they are worth more than any script. First, most denials are procedural rather than clinical, which means most are correctable rather than arguable. Second, the appeal system is barely used, and the small group of people who do use it wins a meaningful share of the time. The most expensive mistake in this entire subject is treating the first denial letter as a verdict. It is worth reading these figures alongside our breakdown of what drives the numbers on a U.S. treatment bill, because a denied claim does not just shift who pays. It changes the total.

The Exact Deadlines and Escalation Ladder for Appealing a Denied Addiction Treatment Claim

Non-grandfathered plans must provide an internal appeals process and access to independent external review. The timeframes below are the federal floor. Some states impose faster ones, and no state may impose slower.

Three provisions in this ladder are worth knowing by heart.

The external reviewer’s decision binds the plan. An independent review organization is not offering an opinion the insurer may weigh. If it decides in your favor, the plan is required to accept it.

In urgent situations you do not have to finish the internal process first. You may request external review at the same time, which matters enormously when someone is mid-detox and a continued stay has just been refused.

And if the plan fails to follow its own required internal appeal procedures, internal remedies can be treated as exhausted, letting you proceed straight to external review. Procedural sloppiness by an insurer is not a delay you have to absorb.

How to Write an Appeal Letter That Answers the Insurer’s Stated Reason Instead of Restating Your Frustration

Appeals fail for a boring reason. They argue that treatment is necessary while the denial was actually about a missing authorization number, a wrong place-of-service code, or a facility that had dropped out of the network three weeks earlier. Read the denial notice for what it literally says, and answer that.

A usable structure, in order:

Open with the identifiers. Member number, claim number, dates of service, facility name, and the exact denial reason quoted from the notice. Nothing else in the first paragraph.

Name the specific plan provision you are relying on, drawn from the summary plan description or evidence of coverage rather than from a general statement about parity.

Attach the clinical documentation mapped dimension by dimension against the criteria the insurer told you it uses, including an explicit statement of why a less intensive level of care is not sufficient. That last sentence is the one reviewers look for.

Close with written requests, numbered so they cannot be answered in a single sentence.

If the plan is employer-sponsored, a copy of the appeal sent to the plan administrator at your employer often changes the tempo. Administrators of self-funded plans carry fiduciary responsibility, and they are frequently unaware of how their third-party administrator is behaving in their name. Our insights and guides index collects the cost research behind the numbers you will be arguing over.

The Public Funding Layer That Sits Underneath Insurance and Is Almost Never Advertised

If insurance will not pay, or there is no insurance, the answer is not automatically self-pay. There is a substantial publicly funded system beneath the commercial one, and it goes largely unused because nobody profits from marketing it.

Every state administers federal substance use prevention and treatment block grant money, directed particularly at people who are uninsured or underinsured. Medicaid covers substance use treatment in expansion states, and in many states it is the single largest payer for addiction care. Opioid settlement funds are now financing treatment capacity that appears on no facility’s price sheet. And a large share of licensed facilities operate sliding fee scales or payment assistance, which you can filter for directly on the federal treatment locator. As we argue across this whole cost library, who pays is very nearly as decisive as what you buy, and it is the factor people research least.

Coverage Traps That Turn an Approved Admission Into an Unexpected Bill Months Later

These are the failure modes we see most often when reviewing how treatment bills are actually constructed, and they sit behind many of the price gaps documented in our global comparison of addiction treatment costs.

Verified benefits treated as guaranteed payment. Verification confirms a policy exists. It does not commit the insurer to anything.

An in-network facility with out-of-network clinicians. The building’s contract and the physician’s contract are separate. Ask about both, and ask specifically about the psychiatrist.

Laboratory billing. Toxicology and confirmatory testing during treatment can generate very large separate claims from a third-party lab you never chose. Ask which lab is used and whether it is in network.

Concurrent review lapsing mid-stay. Coverage stops on the date the authorization stops, not on the date you are discharged.

Institution for mental diseases exclusions in Medicaid. Federal rules restricting Medicaid payment for care in larger residential psychiatric facilities are why residential coverage varies so widely between states, and why a Medicaid enrollee can be approved for care in one state and refused in the next.

Assuming surprise billing protections apply. Federal protections cover emergency services and certain out-of-network care delivered at in-network facilities. Scheduled, elective admission to a facility that is wholly out of network is usually not covered by them.

If you are considering care outside the United States, note that these mechanics stop applying entirely at the border. Our guide to rehab treatment costs in Turkey covers the continuity-of-care and payment questions that most people only think to ask after booking, and the full research archive holds the rest of our cost work.

Free Government and Non-Profit Tools for Verifying Every Claim on This Page Yourself

We would rather you check than trust us. None of these sells your information, and none of them is affiliated with this site or with any facility. Our own editorial standards and sourcing methodology explain what we do with them.

FindTreatment.gov, the federal treatment locator run by SAMHSA, filters licensed facilities by payment type including sliding-scale fees and payment assistance.

HealthCare.gov on internal appeals and on external review, the plain-language version of the deadlines in the table above.

Department of Labor parity guidance, including the model notices and the 2025 enforcement statement.

SAMHSA’s 2024 facility survey, the annual federal census of what treatment facilities offer and which payers they accept.

NIDA’s treatment research, the evidence base on what works, independent of what any facility markets.

The ASAM Criteria overview, for the framework your insurer is applying to the level-of-care decision.

The Limits of This Guide and What Only a Licensed Clinician Can Decide

Because this is information people act on with both their money and their health, it is worth being explicit about how it was produced and where it stops.

Every regulatory, statistical, and legal claim above links to a primary source: federal agency guidance, published survey data, statute, or a non-profit research organization’s analysis of federal reporting. Where a figure is a market observation rather than an official statistic, we say so. Where enforcement policy is unsettled, as it currently is with the 2024 parity regulations, we describe the uncertainty rather than resolving it for narrative convenience.

This content is not reviewed by a physician and we do not claim otherwise. It is not medical, legal, or financial advice. It cannot tell you what level of care is appropriate for a particular person, because that determination requires an assessment by a licensed clinician using validated criteria and no amount of published policy detail substitutes for it. Insurance rules also change on plan-year cycles and vary by state, so anything here should be confirmed against your own plan documents and your own state’s requirements. Where a comparison helps, our country research on how treatment costs differ between health systems and on treatment pricing in Turkey shows how much of an American bill is a product of the payment system rather than the clinical care itself.

More about how this project is funded and why it takes no referral fees is set out on our about page, and the independent cost research library is free to read in full. If you spot an error or a figure that has moved, our contact page is the fastest way to tell us.

References and Citations

Figures and policy positions described above reflect publicly available sources as of July 2026. Insurance rules change on plan-year cycles and vary by state and by plan. Confirm anything material against your own plan documents and your state regulator before acting on it.